Intech Investment Management LLC Purchases New Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Intech Investment Management LLC acquired a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 17,442 shares of the company’s stock, valued at approximately $62,000.

A number of other institutional investors have also recently bought and sold shares of FULC. Assenagon Asset Management S.A. acquired a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth $3,084,000. Bank of New York Mellon Corp acquired a new stake in Fulcrum Therapeutics during the second quarter worth about $1,158,000. Dimensional Fund Advisors LP increased its holdings in Fulcrum Therapeutics by 13.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock valued at $9,182,000 after buying an additional 176,114 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $474,000. Finally, Marshall Wace LLP increased its stake in Fulcrum Therapeutics by 47.7% in the second quarter. Marshall Wace LLP now owns 333,161 shares of the company’s stock valued at $2,066,000 after acquiring an additional 107,588 shares during the last quarter. Institutional investors own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Leerink Partnrs cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. HC Wainwright restated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Finally, Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Fulcrum Therapeutics presently has an average rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $3.99 on Monday. The firm has a 50 day moving average price of $3.47 and a two-hundred day moving average price of $6.03. The stock has a market cap of $215.22 million, a P/E ratio of -12.87 and a beta of 2.14. Fulcrum Therapeutics, Inc. has a 52-week low of $2.86 and a 52-week high of $13.70.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.